Lansing – October 16, 2026 -- Niowave is building an 80,000-square-foot medical radioisotope production facility in Lansing, Michigan, with a capital investment of more than $85 million and operations expected to start in 2028.
Labor Secretary Keith Sonderling toured Niowave's existing dedicated production facility and the construction site of its second plant. He also held a roundtable with company leaders on the production of medical radioisotopes for cancer treatments.
New plant to house up to six linear particle accelerators
The facility will contain up to six new linear particle accelerators and expand Niowave's capacity to produce Actinium-225, an isotope used in targeted alpha therapies for cancer. It will also include production space, radiochemistry laboratories, warehousing and administrative offices.
Project adds at least 73 jobs paying $30.29 per hour
The expansion is expected to create at least 73 jobs with starting wages of $30.29 per hour plus benefits. That is $5.95 above the regional median wage of $24.34 per hour.
State grant of $695,000 backs construction
The project is supported by a $695,000 performance-based grant from the Michigan Business Development Program. Additional state and local funding covers construction, equipment and road improvements.
Domestic supply of critical isotopes is the stated goal
Discussions during the visit covered how the new facility will expand production capacity and strengthen the domestic supply of critical isotopes. The roundtable also addressed recruiting and training specialized talent and the partnerships supporting construction.
Niowave President and CEO Mike Zamiara said the visit showed how Mid-Michigan combines skilled people and a strong manufacturing tradition to tackle tough national challenges, and that the same know-how supports production of isotopes for next-generation cancer treatments.